ArticleJournal of neuro-oncology2015
Stereotactic radiosurgery in the treatment of brain metastases from gastrointestinal primaries.
Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The safety and efficacy of stereotactic radiosurgery in patients with gastrointestinal cancer brain metastasis: a systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review.Medical oncology (Northwood, London, England) · 2017Pooled it
- Machine Learning Prediction of Local Failure in GI Brain Metastases on the Day of Gamma Knife Radiosurgery.Journal of gastrointestinal cancer · 2026Article
- Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases.Advances in radiation oncology · 2025Article
- Concomitant radiosurgical and targeted oncological treatment improves the outcome of patients with brain metastases from gastrointestinal cancer.Radiation oncology (London, England) · 2023Article
- Preoperative Stereotactic Radiosurgery for Glioblastoma.Biology · 2022Review
- The Cognitive Effects of Radiotherapy for Brain Metastases.Frontiers in oncology · 2022Review
- Treatment of brain metastases from gastrointestinal primaries: Comparing whole-brain radiotherapy and stereotactic radiosurgery in terms of survival.Northern clinics of Istanbul · 2022Article
- Proton beam radiosurgery: early clinical results.Translational cancer research · 2019Article
- Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers.Journal of radiosurgery and SBRT · 2019Article
- Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases.International journal of molecular sciences · 2018Review
- Stereotactic radiosurgery for brain metastases from malignant melanoma and the impact of hemorrhagic metastases.Journal of neuro-oncology · 2018Article
- Stereotactic radiosurgery for small brain metastases and implications regarding management with systemic therapy alone.Journal of neuro-oncology · 2017Article
- Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy.Radiation oncology (London, England) · 2017Article
- Stereotactic Radiosurgery Results for Patients With Brain Metastases From Gastrointestinal Cancer: A Retrospective Cohort Study of 802 Patients With GI-GPA Validity Test.Advances in radiation oncologyArticle
- Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effectsOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases from gastrointestinal (GI) primary malignancies are generally less common than those arising from other primary locations. Our purpose was to analyze the efficacy of stereotactic radiosurgery (SRS) in the treatment of patients with brain metastases from GI malignancies in the modern radiosurgical and systemic therapy era. A review of patients treated with SRS to brain metastases from GI primaries treated from 1996 to 2015 at our institution was conducted. Clinical, therapeutic, dosimetric and radiographic characteristics were collected and analyzed for an association with brain tumor local control (LC) and overall survival (OS) following SRS using univariate and multivariate (MVA) analyses. 261 brain metastases were identified from 86 patients meeting inclusion criteria. The most common primary location was rectum (n = 36). LC was 94.1 % at last follow up and margin dose ≥20 Gy was associated with improved LC on MVA (p = 0.038). Median OS was 6.2 months and was improved with higher performance score and luminal primary location on MVA (p = 0.002 and 0.015, respectively). Tumor histology, whole brain irradiation, targeted therapies, and antineoplastic therapies were not associated with improved LC or OS on MVA. SRS provides favorable LC of brain metastases of GI origin, and margin doses of at least 20 Gy should be considered when clinically appropriate. Compared to non-luminal primaries, patients with brain metastases from a luminal primary demonstrate improved OS.
Indexed as
Identifiers
26186901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.